TherapeuticsMD, Inc. (TXMD)
$
2.16
-0.14 (-6.48%)
Key metrics
Financial statements
Free cash flow per share
0.1787
Market cap
26.6 Million
Price to sales ratio
9.5211
Debt to equity
0.2362
Current ratio
2.4609
Income quality
9.8009
Average inventory
0
ROE
0.0111
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States, focusing on various therapeutic solutions such as IMVEXXY for moderate-to-severe dyspareunia and BIJUVA, which combines bio-identical hormone therapy of 17ß-estradiol and progesterone to treat moderate-to-severe vasomotor symptoms. The company also offers ANNOVERA, a ring-shaped contraceptive vaginal system. As part of its ongoing innovation, TherapeuticsMD is developing preclinical projects including TX-005HR, a progesterone-only transdermal cream; TX-006HR, a combination estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, both of which are transdermal patch candidates; and TX-009HR, an oral formulation containing progesterone and estradiol. Additionally, TherapeuticsMD manufactures and distributes both branded and generic prescription prenatal vitamins under several brands such as vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1. The company's prescription pharmaceutical products and prenatal vitamins are sold to wholesale and retail pharmacy distributors. In the fiscal year 2024 the company incurred an interest expense of $9,500.00 reflecting its debt servicing obligations. The operating income ratio is -2.70 indicating the company's operational profitability margin. The company's stock is identified with the symbol 'TXMD' in the market, and the weighted average number of shares outstanding is 11,532,000.00 highlighting the company's shareholder base. TherapeuticsMD, Inc. is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. With a market capitalization of $25,000,622.00 the company is classified as a small-cap player. The stock is affordable at $1.09 making it suitable for budget-conscious investors. However, it has a low average trading volume of 132,031.00 indicating lower market activity. Furthermore, TherapeuticsMD belongs to the Healthcare sector, driving innovation and growth within the healthcare market. This strategic positioning not only enhances its market presence but also emphasizes its commitment to addressing the unique healthcare needs of women in the United States.
Is TherapeuticsMD, Inc. (TXMD) a good investment?
Investing in TherapeuticsMD, Inc. (TXMD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is TherapeuticsMD, Inc. (TXMD)'s stock forecast?
Analysts predict TherapeuticsMD, Inc. stock to fluctuate between $0.72 (low) and $2.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is TherapeuticsMD, Inc.'s market capitalization?
As of 2026-01-30, TherapeuticsMD, Inc.'s market cap is $25,000,622, based on 11,574,362 outstanding shares.
How does TherapeuticsMD, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., TherapeuticsMD, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy TherapeuticsMD, Inc. (TXMD) stock?
To buy TherapeuticsMD, Inc. (TXMD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TXMD. Place an order (Market, Limit, etc.).
What is the best time to invest in TherapeuticsMD, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has TherapeuticsMD, Inc. stock ever split?
TherapeuticsMD, Inc.'s last stock split was 1:50 on 2022-05-09.
How did TherapeuticsMD, Inc. perform in the last earnings report?
Revenue: $1,761,000 | EPS: -$0.19 | Growth: -65.45%.
Where can I find TherapeuticsMD, Inc.'s investor relations reports?
Visit https://www.therapeuticsmd.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for TherapeuticsMD, Inc.?
You can explore historical data from here
What is the all-time high and low for TherapeuticsMD, Inc. stock?
All-time high: $49 (2021-08-06) | All-time low: $0.70 (2024-12-31).
What are the key trends affecting TherapeuticsMD, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
3 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.
businesswire.com
6 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted.
businesswire.com
9 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and diluted common share, a decrease of $99 thousand, compared to net loss from continuing operations of $(8.
businesswire.com
10 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) m.
benzinga.com
a year ago
The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
businesswire.com
2 years ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.
businesswire.com
2 years ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. “We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operati.
businesswire.com
2 years ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. “As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty assets,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Third Quarter 2023 Financial Res.
businesswire.com
2 years ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. “The Company's transformation into a royalty-based business is ongoing. As we phase out our historical business operations, we remain focused on reducing costs and conserving cash,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Second Q.
businesswire.com
3 years ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations.
See all news
